Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009;48(4):211-41.
doi: 10.2165/00003088-200948040-00001.

Drug interactions with new and investigational antiretrovirals

Kevin C Brown  1 , Sunita Paul, Angela D M Kashuba
Affiliations
Review

Drug interactions with new and investigational antiretrovirals

Kevin C Brown et al. Clin Pharmacokinet. 2009.

Abstract

More than 20 individual and fixed-dose combinations of antiretrovirals are approved for the treatment of human immunodeficiency virus (HIV) infection. However, owing to the ongoing limitations of drug resistance and adverse effects, new treatment options are still required. A number of promising new agents in existing or new drug classes are in development or have recently been approved by the US FDA. Since these agents will be used in combination with other new and existing antiretrovirals, understanding the potential for drug interactions between these compounds is critical to their appropriate use. This article summarizes the drug interaction potential of new and investigational protease inhibitors (darunavir), non-nucleoside reverse transcriptase inhibitors (etravirine and rilpivirine), chemokine receptor antagonists (maraviroc, vicriviroc and INCB 9471), integrase inhibitors (raltegravir and elvitegravir) and maturation inhibitors (bevirimat).

PubMed Disclaimer

Conflict of interest statement

The other authors have no conflicts of interest that are directly relevant to the content of this review.

Figures

Fig. 1
Fig. 1
Chemical structures of (a) darunavir, (b) etravirine, (c) rilpivirine, (d) maraviroc, (e) vicriviroc, (f) INCB 9471 (g) raltegravir, (h) elvitegravir and (i) bevirimat.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Prezista® (darunavir) tablet: US prescribing information. Raritan (NJ): Tibotec Therapeutics, 2008 Dec. [2009 Mar 25]. [online]. Available from URL: http://www.prezista.com/prezista/documents/us_package_insert.pdf.
    1. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005 Jun;49(6):2314–21. - PMC - PubMed
    1. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007 Dec;81(24):13845–51. - PMC - PubMed
    1. Sekar V, Spinosa-Guzman S, Lefebvre E, et al. Clinical pharmacology of TMC114 – a potent HIV protease inhibitor. XVI International AIDS Conference; 2006 Aug 13-18; Toronto (ON). abstract no. TUPE0083.
    1. Sekar V, De Meyer S, Vangeneugden T, et al. Pharmacokinetic/pharmacodynamic analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-8; Denver (CO).

Publication types

MeSH terms